Primary tumor histology and location as predictive factors for clinical outcome in metastatic gastric cancer (GC) patients receiving first-line chemotherapy.

e15081 Background: Recently, a new classification for GC has been proposed, based on Lauren’s histology and on anatomic tumour location, identifying three subtypes of disease: type 1 (proximal non diffuse GC), type 2 (diffuse GC) and type 3 (distal non diffuse GC). Aim of our analysis was to compare clinical outcome, in terms of response rate (RR), progression-free survival (PFS), and overall survival (OS), according to different GC subtypes (1, 2, 3) in metastatic GC patients (pts) receiving first-line chemotherapy. Methods: Advanced GC pts treated with a first-line combination chemotherapy were included in our analysis. Pts were divided in three subgroups (type 1, type 2, and type 3) as previously defined. Results: A total of 248 advanced GC pts were included: most of pts belonged to type 2 (45.15%) and type 3 (43.55%); type 1 included 28 pts (11.30%). The majority of pts (65.4%) received a fluoropyrimidine-based chemotherapy doublet while the remaining 88 pts received a three drugs regimen including a ...